Sotatercept Leads to PVR Reductions in Pulmonary Arterial Hypertension
In patients with pulmonary arterial hypertension (PAH) receiving background therapy, treatment with sotatercept led to significant reductions in pulmonary vascular resistance.
Pulmonary Hypertension
Pulmonary Hypertension Increases Mortality Risk in Patients Undergoing Mitral Valve Surgery
The researchers’ goals included determining how postoperative residual pulmonary hypertension was related to longitudinal mortality in patients with severe mitral regurgitation who had mitral valve surgery.
Riociguat May Be Useful Alternative to PDE5i Therapy in Pulmonary Arterial Hypertension
Riociguat may be a useful option for patients with pulmonary arterial hypertension in whom phosphodiesterase-5 inhibitor treatment is insufficient.
Iron Supplementation Has No Clinical Benefit in Pulmonary Arterial Hypertension
Patients with pulmonary arterial hypertension and iron deficiency in the absence of anemia who received iron supplements did not show significant clinical benefit at 12 weeks.
Acute Pulmonary Hypertension Associated With Increased Mortality in COVID-19
Critically ill patients with COVID-19 and concurrent acute pulmonary hypertension were associated with signs of cardiac failure and increased mortality.
Pulmonary Hypertension-COPD May Have Poorer Prognosis vs Idiopathic PAH
Patients with pulmonary hypertension and COPD appear to have a poorer prognosis than those with idiopathic pulmonary arterial hypertension.
Uric Acid Level as Noninvasive Indicator of Pulmonary Arterial Hypertension Severity
Since uric acid levels in patients with idiopathic pulmonary arterial hypertension are associated with an impaired clinical and hemodynamic profile, they may serve as a useful noninvasive indicator of disease severity.
High Hepatic Growth Factor Levels Add Predictive Value to PAH Risk Score
In pulmonary arterial hypertension, high plasma levels of hepatic growth factor are associated with the right heart maladaptive phenotype and are incremental to the REVEAL score for the prediction of patient outcomes.
Inhaled Treprostinil Improves Exercise Capacity in ILD-Related Pulmonary Hypertension
Patients with pulmonary hypertension caused by interstitial lung disease experienced greater improvements in exercise capacity with inhaled treprostinil compared with placebo.
Utility of Pulmonary Arterial Hypertension Screening in Adults With BMPR2 Mutation
Asymptomatic carriers of the BMPR2 mutation have a significant risk of developing incident pulmonary arterial hypertension.
- Loading...
Loading...
Next post in Pulmonary Hypertension
Loading... 
Loading...